# ERF

## Overview
The ERF gene encodes the ETS2 repressor factor, a transcription factor that plays a crucial role in regulating gene expression by acting as a transcriptional repressor. This protein is part of the ETS family of transcription factors, characterized by the presence of an ETS DNA-binding domain, which allows it to bind specific DNA sequences and modulate transcriptional activity (Twigg2013Reduced). ERF is involved in various cellular processes, including cell cycle regulation and osteogenesis, and functions as a downstream effector in the receptor tyrosine kinase (RTK)-ERK signaling pathway (Le2004ERF; Vogiatzi2023Development). The protein's activity is regulated by phosphorylation, which influences its nuclear localization and transcriptional repression capabilities (Twigg2013Reduced). Mutations in the ERF gene have been linked to clinical conditions such as craniosynostosis and Chitayat syndrome, as well as an increased risk of certain cancers, underscoring its significance in both developmental and pathological contexts (CannonAlbright2021A; Orsini2024An; Balasubramanian2016Chitayat).

## Structure
The ERF (ETS2 repressor factor) protein is a transcription factor encoded by the ERF gene, located on chromosome 19q13.2. It consists of 548 amino acids and includes several functionally significant domains. The primary structure features an ETS DNA-binding domain, which is crucial for its interaction with specific DNA sequences, targeting a core motif (5′-GGA A / T -3′) (Twigg2013Reduced). This domain is conserved across different ETS subfamily members, underscoring its importance in the protein's function (Twigg2013Reduced).

The ERF protein also contains a central ERK interaction domain and C-terminal repressor domains, which contribute to its role as a negative regulator by either competing with other ETS-family members for DNA binding or through unique targets (Twigg2013Reduced). Post-translational modifications, such as phosphorylation by ERK1/2, regulate its activity by promoting nuclear export, thus modulating its transcriptional repression capabilities (Twigg2013Reduced).

Mutations in the ERF gene, including missense changes, splice site mutations, and nonsense changes, often lead to reduced expression of full-length ERF, particularly affecting its function in osteogenesis and its association with craniosynostosis (Twigg2013Reduced). The protein's interaction with other proteins and DNA is essential for its regulatory roles (Twigg2013Reduced).

## Function
The ERF (ETS2 Repressor Factor) gene encodes a transcriptional repressor that plays a significant role in regulating cell proliferation and the cell cycle, particularly during the G1 phase. ERF functions as a downstream effector in the receptor tyrosine kinase (RTK)-ERK signaling pathway, where its activity is modulated by phosphorylation. This phosphorylation leads to its nuclear export and subsequent inactivity, linking ERK activity to cell cycle progression (Le2004ERF; Vogiatzi2023Development).

In its non-phosphorylated state, ERF can induce cell cycle arrest in the G1 phase, requiring the presence of the wild-type retinoblastoma protein. This arrest can be suppressed by cyclin overexpression, indicating ERF's role in regulating the cell cycle machinery (Le2004ERF). ERF's nuclear localization is crucial for its function, as it can arrest cell cycle progression in an Rb-dependent manner, suggesting interference with specific cell cycle components at the G1 restriction point (Le2004ERF).

ERF is also involved in cranial bone development, where it regulates the differentiation of mesenchymal stem/progenitor cells toward the osteogenic lineage. Insufficiency of ERF can lead to craniosynostosis, a condition characterized by premature suture closure in the skull (Vogiatzi2023Development).

## Clinical Significance
Mutations in the ERF gene are associated with several clinical conditions, most notably craniosynostosis, a disorder characterized by the premature fusion of skull sutures. This condition can manifest in both syndromic and non-syndromic forms, with ERF mutations accounting for approximately 2% of syndromic and 0.7% of non-syndromic cases (Orsini2024An). Individuals with ERF-related craniosynostosis may exhibit multiple suture synostosis, craniofacial dysmorphism, Chiari malformation, and developmental delays (Orsini2024An). The mutations are often missense or frameshift, affecting critical domains of the ERF protein, such as the DNA-binding or repression domains, impairing its regulatory function (Orsini2024An).

ERF mutations have also been linked to Chitayat syndrome, a rare condition characterized by hyperphalangism, facial dysmorphism, and respiratory issues. This syndrome is associated with a specific recurrent mutation, p.(Tyr89Cys), in the ERF gene (Balasubramanian2016Chitayat). Additionally, ERF has been implicated in cancer predisposition, with rare variants in the gene associated with increased risk for bladder and prostate cancers (CannonAlbright2021A). These findings highlight the diverse clinical significance of ERF mutations, affecting both cranial development and cancer susceptibility.

## Interactions
ERF (ETS2 repressor factor) is known to interact with several proteins and nucleic acids, playing a significant role in transcriptional repression. ERF specifically interacts with the N terminus of histone deacetylase 1 (HDAC1), a chromatin remodeling enzyme, but not with its C terminus. This interaction is as strong as the interaction between HDAC1 and the IE2-p86 protein, which serves as a positive control. ERF also interacts with HDAC3, suggesting its role in recruiting multiple co-repressor/chromatin remodeling proteins to inhibit the major immediate-early promoter (MIEP) activity of human cytomegalovirus (HCMV) (Wright2005Ets2).

ERF associates with HDAC1 in cell extracts, as demonstrated by GST-fusion pull-down assays and immunoprecipitation assays, confirming the interaction between ERF and endogenous HDAC1. This interaction is specific, as shown by the lack of signal with a control antibody. ERF is associated with functional deacetylase activity, indicating that the HDAC1 associated with ERF is enzymically active. Co-transfection assays reveal that ERF and HDAC1 act together to repress the MIEP of HCMV, with a more than additive decrease in MIEP activity when both are present (Wright2005Ets2).

ERF also interacts with the prolactin (PRL) gene promoter, inhibiting prolactin promoter activity by disrupting the cooperative interactions between the pituitary-specific POU domain protein Pit-1 and members of the ETS transcription factor family. ERF specifically interferes with Pit-1 binding to DNA elements within the PRL promoter, which are necessary for multihormonal regulation of transcriptional activity (Day1998Selective).


## References


[1. (Vogiatzi2023Development) Angeliki Vogiatzi, Kleoniki Keklikoglou, Konstantinos Makris, Dionysia Stamatia Argyrou, Athanasios Zacharopoulos, Varvara Sotiropoulou, Nikolaos Parthenios, Angelos Gkikas, Maria Kokkori, Melodie S. W. Richardson, Aimée L. Fenwick, Sofia Archontidi, Christos Arvanitidis, Jeremy Robertson, John Parthenios, Giannis Zacharakis, Stephen R. F. Twigg, Andrew O. M. Wilkie, and George Mavrothalassitis. Development of erf-mediated craniosynostosis and pharmacological amelioration. International Journal of Molecular Sciences, 24(9):7961, April 2023. URL: http://dx.doi.org/10.3390/ijms24097961, doi:10.3390/ijms24097961. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms24097961)

[2. (Orsini2024An) Alessandro Orsini, Andrea Santangelo, Alessandra Carmignani, Anna Camporeale, Francesco Massart, Nina Tyutyusheva, Diego Giampietro Peroni, Thomas Foiadelli, Alessandro Ferretti, Benedetta Toschi, Silvia Romano, and Alice Bonuccelli. An ultra-rare mixed phenotype with combined ap-4 and erf mutations: the first report in a pediatric patient and a literature review. Genes, 15(4):436, March 2024. URL: http://dx.doi.org/10.3390/genes15040436, doi:10.3390/genes15040436. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes15040436)

[3. (CannonAlbright2021A) Lisa Anne Cannon-Albright, Craig Carl Teerlink, Jeff Stevens, Franklin W. Huang, Csilla Sipeky, Johanna Schleutker, Rolando Hernandez, Julio Facelli, Neeraj Agarwal, and Donald L. Trump. A rare variant in erf (rs144812092) predisposes to prostate and bladder cancers in an extended pedigree. Cancers, 13(10):2399, May 2021. URL: http://dx.doi.org/10.3390/cancers13102399, doi:10.3390/cancers13102399. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers13102399)

[4. (Balasubramanian2016Chitayat) M Balasubramanian, H Lord, S Levesque, H Guturu, F Thuriot, G Sillon, A M Wenger, D L Sureka, T Lester, D S Johnson, J Bowen, A R Calhoun, D H Viskochil, G Bejerano, J A Bernstein, and D Chitayat. Chitayat syndrome: hyperphalangism, characteristic facies, hallux valgus and bronchomalacia results from a recurrent c.266a&gt;g p.(tyr89cys) variant in theerfgene. Journal of Medical Genetics, 54(3):157–165, October 2016. URL: http://dx.doi.org/10.1136/jmedgenet-2016-104143, doi:10.1136/jmedgenet-2016-104143. This article has 18 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmedgenet-2016-104143)

[5. (Wright2005Ets2) Edward Wright, Mark Bain, Linda Teague, Jane Murphy, and John Sinclair. Ets-2 repressor factor recruits histone deacetylase to silence human cytomegalovirus immediate-early gene expression in non-permissive cells. Journal of General Virology, 86(3):535–544, March 2005. URL: http://dx.doi.org/10.1099/vir.0.80352-0, doi:10.1099/vir.0.80352-0. This article has 55 citations and is from a peer-reviewed journal.](https://doi.org/10.1099/vir.0.80352-0)

[6. (Day1998Selective) Richard N. Day, Jeffrey Liu, Valdine Sundmark, Margaret Kawecki, Diana Berry, and Harry P. Elsholtz. Selective inhibition of prolactin gene transcription by the ets-2 repressor factor. Journal of Biological Chemistry, 273(48):31909–31915, November 1998. URL: http://dx.doi.org/10.1074/jbc.273.48.31909, doi:10.1074/jbc.273.48.31909. This article has 23 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.273.48.31909)

[7. (Twigg2013Reduced) Stephen R F Twigg, Elena Vorgia, Simon J McGowan, Ioanna Peraki, Aimée L Fenwick, Vikram P Sharma, Maryline Allegra, Andreas Zaragkoulias, Elham Sadighi Akha, Samantha J L Knight, Helen Lord, Tracy Lester, Louise Izatt, Anne K Lampe, Shehla N Mohammed, Fiona J Stewart, Alain Verloes, Louise C Wilson, Chris Healy, Paul T Sharpe, Peter Hammond, Jim Hughes, Stephen Taylor, David Johnson, Steven A Wall, George Mavrothalassitis, and Andrew O M Wilkie. Reduced dosage of erf causes complex craniosynostosis in humans and mice and links erk1/2 signaling to regulation of osteogenesis. Nature Genetics, 45(3):308–313, January 2013. URL: http://dx.doi.org/10.1038/ng.2539, doi:10.1038/ng.2539. This article has 136 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ng.2539)

[8. (Le2004ERF) Lionel Le Gallic, Laura Virgilio, Philip Cohen, Benoit Biteau, and George Mavrothalassitis. Erf nuclear shuttling, a continuous monitor of erk activity that links it to cell cycle progression. Molecular and Cellular Biology, 24(3):1206–1218, February 2004. URL: http://dx.doi.org/10.1128/mcb.24.3.1206-1218.2004, doi:10.1128/mcb.24.3.1206-1218.2004. This article has 75 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.24.3.1206-1218.2004)